Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...4950515253545556575859...136137»
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Utilizing Efgartigimod on Refractive Pembrolizumab-Induced Myasthenia Gravis-Like Syndrome: A Case Report () -  Oct 17, 2022 - Abstract #ANA2022ANA_676;    
    Initiation of Efgartigimod therapy led to early improvement of her drug-induced myasthenia gravis and platelet count following the development of severe thrombocytopenia, a recognized side effect of PLEX. Further research into the use of Efgartigimod in similar patients is necessary, but we propose an alternative treatment.
  • ||||||||||  levetiracetam / Generic mfg.
    Diversity of Neurologic Disorders at a Free Neurology Community Health Clinic () -  Oct 17, 2022 - Abstract #ANA2022ANA_434;    
    The diverse patient population offers the opportunity for clinicians in training to and give back to their community. Further investigation into resident feedback can provide insight on the clinic’s impact on resident education and wellness.
  • ||||||||||  Trial primary completion date, Real-world evidence, Real-world:  The Impact of Myasthenia Gravis in the Real World (clinicaltrials.gov) -  Oct 17, 2022   
    P=N/A,  N=2000, Recruiting, 
    Further investigation into resident feedback can provide insight on the clinic’s impact on resident education and wellness. Trial primary completion date: Nov 2021 --> Dec 2022
  • ||||||||||  Journal:  Enrichment of serum IgG4 in MuSK myasthenia gravis patients. (Pubmed Central) -  Oct 15, 2022   
    Correlation analyses suggest MuSK-specific antibodies do not solely explain the variation in IgG4 levels. In conclusion, although serum IgG4 levels are slightly increased, the levels do not support ubiquitous IgG4 responses in MuSK MG patients as the underlying cause of dominant IgG4 MuSK antibodies.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Complement and myasthenia gravis. (Pubmed Central) -  Oct 14, 2022   
    In this review, evidence for the importance of complement, and possible relationships between autoantigen, autoantibodies, complement activation, and the destruction of the membrane are discussed. More recent insights from the results of the complement-inhibiting therapeutic antibody eculizumab are also described, and the mechanisms connecting antibody binding to complement activation are considered from a structural viewpoint.
  • ||||||||||  metformin / Generic mfg.
    Biomarker, Journal:  Metformin Inhibits the Pathogenic Functions of AChR-specific B and Th17 Cells by Targeting miR-146a. (Pubmed Central) -  Oct 14, 2022   
    We also investigated the downstream target genes of miR-146a in both T and B cells using bioinformatics screening and qPCR. Taken together, our study identifies a complex role of miR-146a in the EAMG rat model, suggesting that more caution should be paid in targeting miR-146a for the treatment of MG.
  • ||||||||||  prednisone / Generic mfg.
    Immune Complex Tubulointerstitial Nephritis: An Unusual Presentation of Anti-LRP2 Nephropathy (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1028;    
    Patient was started on prednisone 60 mg daily which was tapered two months after initiation due to complicating nocardia infection...It is also possible that antibodies to antigens other than LDL receptor-related protein 2 may be playing a role in the pathophysiology of ABBA disease. Our case highlights the need for further investigation into the association of ABBA with anti-LRP2 nephropathy.
  • ||||||||||  prednisone / Generic mfg.
    Post Thymectomy: An Example of Immune Dysregulation? (Exhibit Hall (Upper Concourse); Monitor 08) -  Oct 10, 2022 - Abstract #ACAAI2022ACAAI_992;    
    She was started on Prednisone 60 mg PO daily...The incidence of numerous AD's has been recognized in thymectomized patients; however, data is scarce regarding IgG4-RD. The role of thymectomy in the development of IgG4-RD remains to be elucidated.
  • ||||||||||  Examining links between general fatigue in myasthenia gravis with objectively measured sleep (SDCC Halls B-H) -  Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_8887;    
    Out of the two scored home sleep apnea tests, one control (48, female) participant was found to have no sleep apnea, and one MG participant (49, male) was found to have mild sleep apnea. Since sleep disorders are readily treatable, if obstructive sleep apnea and/or poor-quality sleep are found to significantly contribute to general fatigue in MG, this would provide a novel treatment target to address the common yet debilitating impact of general fatigue in MG.
  • ||||||||||  Differential effects of calcium channel mutations on (R)-roscovitine analog-mediated slowed deactivation (SDCC Halls B-H) -  Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_6746;    
    We further present several exploratory single-residue mutations of CaV2-specific inner pore residues, selected based on computer models of drug binding in CaV2 channels, that have differential effects on KK-20’s open-state-prolonging effect and concentration-dependence of binding. Finally, we present the results of a preliminary investigation into the hypothesis (based on our site-directed mutagenesis findings) that (R)-roscovitine analog binding disrupts residue interactions that couple voltage sensor deactivation with pore closure.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Journal:  "Plasma exchange in a bottle": An overview of efgartigimod for apheresis practitioners. (Pubmed Central) -  Oct 7, 2022   
    Apheresis practitioners, especially those managing long-term apheresis in seropositive individuals, may therefore see some of their patients transitioned from plasma exchange to efgartigimod. Long-term experience with efgartigimod remains lacking and studies are needed to establish the role of efgartigimod in the acute setting.
  • ||||||||||  Journal:  COVID-19-associated damage of the peripheral nervous system (Pubmed Central) -  Oct 5, 2022   
    SARS-CoV-2 can trigger various stages of pathogenesis, including neuroimmune ones, which cause long-term consequences of COVID-19, including those associated with the damage of the peripheral nervous system. Awareness of COVID-19-associated pathological conditions will allow assessment of the possible risks of damage of the peripheral nervous system, recognize them at early stages and develop more effective approaches for treatment.
  • ||||||||||  Journal:  Editorial: Phenotypes of myasthenia gravis. (Pubmed Central) -  Oct 4, 2022   
    Complete resection should be achieved, even though extensive vascular reconstructions are required. No abstract available
  • ||||||||||  Journal, Checkpoint inhibition:  Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. (Pubmed Central) -  Oct 4, 2022   
    We review previously used inclusion criteria and suggest an expertise-based classification criterion to provide a standardized definition and allow comparability between studies. There is a critical need for prospective translational and clinical studies that elucidate the pathophysiology of ICI myositis in order to improve evaluation and management of these patients.
  • ||||||||||  azathioprine / Generic mfg.
    Review, Journal:  Myasthenia gravis complicating the surgical management of achondroplasia: a case-based update. (Pubmed Central) -  Oct 4, 2022   
    There is a critical need for prospective translational and clinical studies that elucidate the pathophysiology of ICI myositis in order to improve evaluation and management of these patients. We report the first case of myasthenia gravis in achondroplasia and review implications in the management.
  • ||||||||||  Review, Journal:  A review of surgical management of progressive myogenic ptosis. (Pubmed Central) -  Oct 1, 2022   
    This intentional under-correction subsequently increases susceptibility for ptosis recurrence. Myogenic ptosis repair therefore requires delicate balancing between function, sustained repair, and corneal protection.
  • ||||||||||  Review, Journal:  Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis. (Pubmed Central) -  Oct 1, 2022   
    In contrast, inflammation and volume increases are often observed in acquired muscle diseases such as Graves' orbitopathy. In diseases with ophthalmoparesis and ptosis specific patterns of clinical symptoms, the EOM involvement pattern and orbital imaging provide valuable information for diagnosis and could prove valuable in the follow-up of disease progression and the understanding of disease pathophysiology.